Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR018 phase II trial of NGR-hTNF plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer
2010-023613-61Phase 2Completed
- Sponsor
- MolMed
- Start
- May 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing NGR-hTNF plus pegylated liposomal doxorubicin with Pegylated liposomal doxorubicin (2 arms). Primary endpoint: progression-free survival. Started May 2011; status: completed.
02
Drugs
NGR-TNFdoxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2010-023613-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023613-61.